tbc1d7 Antibody

What is TBC1D7 and why is it important in cellular research?

TBC1D7 has been identified as the third core subunit of the TSC1-TSC2 complex (tuberous sclerosis complex), a critical negative regulator of cell growth. It functions through a GTPase-activating protein (GAP) activity toward Rheb, which inhibits the mechanistic target of rapamycin complex 1 (mTORC1), a key promoter of cell growth . Its importance extends beyond this pathway, as recent research in Drosophila models shows TBC1D7 plays a significant role in regulating systemic growth independently of TSC, particularly through its specific expression in insulin-producing cells in the fly brain where it regulates biosynthesis and release of insulin-like peptide 2 . This dual functionality makes TBC1D7 a critical target for research into growth regulation, metabolic disorders, and related pathologies.

What are the common applications for TBC1D7 antibodies in research?

TBC1D7 antibodies are primarily utilized in:

• Western blotting: For detecting and quantifying TBC1D7 protein levels and validating knockdown or overexpression experiments

• Immunoprecipitation: To study protein-protein interactions with TSC1, TSC2, and other potential binding partners

• Immunofluorescence: For examining subcellular localization of TBC1D7, though finding specific antibodies for this application has been challenging

• ELISA: For quantitative detection of TBC1D7 in various samples

• Fractionation studies: For analyzing TBC1D7 distribution in different cellular compartments and protein complexes

These applications are essential for investigating TBC1D7's role in the TSC-TBC complex and its independent functions in growth regulation and insulin signaling.

What are the key considerations when selecting a TBC1D7 antibody for research?

When selecting a TBC1D7 antibody, researchers should consider:

• Specificity: Validate antibody specificity through siRNA-mediated knockdown controls to ensure signals are genuinely from TBC1D7

• Target epitope: Antibodies targeting different regions (N-terminal, middle region, or C-terminal) may yield different results depending on protein folding and complex formation

• Cross-reactivity: Consider species cross-reactivity if working with model organisms; some TBC1D7 antibodies react with human, mouse, rat, rabbit, bovine, dog, goat, guinea pig, and horse proteins

• Validated applications: Ensure the antibody has been validated for your specific application (WB, IP, IF, ELISA)

• Publication record: Prefer antibodies with demonstrated use in peer-reviewed publications

• Lot-to-lot consistency: Request data on lot-to-lot variation to ensure reproducible results

Testing multiple antibodies in parallel is often necessary to identify the most suitable reagent for specific experimental conditions.

How can TBC1D7 antibodies help elucidate its role in the TSC-TBC complex versus its independent functions?

TBC1D7 antibodies are crucial tools for distinguishing between TBC1D7's TSC-dependent and independent functions. Researchers can employ several sophisticated approaches:

• Co-immunoprecipitation with fractionation: Using TBC1D7 antibodies for immunoprecipitation followed by sucrose density gradient fractionation can separate TBC1D7 populations associated with the TSC complex from independent pools. Research shows approximately 40-50% of total cellular TBC1D7 associates with the TSC1-TSC2 complex, while the remainder exists in a free pool .

• Proximity labeling coupled with immunoprecipitation: This approach can identify novel TBC1D7 interaction partners independent of TSC1-TSC2.

• Tissue-specific immunohistochemistry: Using TBC1D7 antibodies in different tissues can reveal expression patterns that correlate with TSC-independent functions, such as its specific expression in insulin-producing cells in the fly brain .

• Comparative studies in TSC1/TSC2-null backgrounds: TBC1D7 antibodies can detect remaining TBC1D7 in TSC1 or TSC2 knockout models to study its behavior and localization in the absence of the complex partners.

These approaches can help distinguish between TBC1D7's dual roles in regulating mTORC1 through the TSC complex and its independent functions in systemic growth regulation through insulin signaling.

What are the challenges in detecting endogenous versus overexpressed TBC1D7 protein, and how can antibody selection address these issues?

Detecting endogenous TBC1D7 presents several challenges compared to overexpressed protein:

To address these challenges:

• Use highly specific antibodies validated for endogenous detection

• Employ appropriate positive and negative controls (siRNA knockdown)

• Consider using mCherry knock-in approaches as demonstrated in Drosophila models

• Validate antibodies across multiple applications to ensure consistent results

How can researchers use TBC1D7 antibodies to investigate the protein's role in pathological conditions?

TBC1D7 antibodies can be valuable tools for investigating its role in various pathological conditions:

• Tuberous Sclerosis Complex (TSC): While TSC is primarily associated with mutations in TSC1 or TSC2, TBC1D7 antibodies can help assess how TBC1D7 expression, stability, and complex formation are affected in TSC patient samples. This can provide insights into compensatory mechanisms and potential therapeutic targets.

• Intellectual Disability and Megalencephaly: Loss of TBC1D7 has been associated with intellectual disability and megalencephaly, distinct from classic TSC . TBC1D7 antibodies can be used in immunohistochemistry and Western blot analyses of brain tissues to study expression patterns and protein interactions in these conditions.

• Growth Disorders: Given TBC1D7's role in regulating systemic growth through insulin signaling , antibodies can be used to assess its expression in growth disorders.

• Metabolic Conditions: TBC1D7's involvement in insulin production suggests a potential role in metabolic diseases. Antibodies can be used to examine expression in pancreatic tissues and insulin-producing cells.

• Cancer Research: As a negative regulator of mTORC1, TBC1D7 may have tumor suppressor properties. Antibodies can help assess its expression, localization, and complex formation in tumor samples.

These applications require careful validation of antibody specificity in the relevant tissue contexts and appropriate controls to ensure reliable results.

What is the optimal protocol for immunoprecipitation of the TSC1-TSC2-TBC1D7 complex using TBC1D7 antibodies?

Based on published research, here is an optimized protocol for immunoprecipitation of the TSC-TBC complex:

Materials:

• Validated TBC1D7 antibody (preferably one that has been demonstrated to immunoprecipitate endogenous TBC1D7)

• Protein A/G magnetic or agarose beads

• Lysis buffer: 40 mM HEPES (pH 7.4), 120 mM NaCl, 1 mM EDTA, 10 mM pyrophosphate, 10 mM β-glycerophosphate, 50 mM NaF, 1.5 mM Na3VO4, 0.3% CHAPS, and protease inhibitors

Protocol:

• Cell lysis: Lyse cells in CHAPS-containing buffer (as detailed above) to preserve complex integrity. The use of CHAPS instead of stronger detergents is critical for maintaining the TSC1-TSC2-TBC1D7 interaction .

• Pre-clearing: Pre-clear the lysate with protein A/G beads for 1 hour at 4°C to reduce non-specific binding.

• Immunoprecipitation: Incubate pre-cleared lysate with TBC1D7 antibody (typically 2-5 μg per mg of total protein) overnight at 4°C with gentle rotation.

• Bead binding: Add protein A/G beads and incubate for 2-3 hours at 4°C.

• Washing: Wash beads 4-5 times with lysis buffer containing 0.1% CHAPS.

• Elution: Elute bound proteins with SDS sample buffer and heat at 95°C for 5 minutes.

• Analysis: Analyze the immunoprecipitated complex by Western blotting using antibodies against TBC1D7, TSC1, and TSC2.

Critical considerations:

• Temperature must be maintained at 4°C throughout to preserve complex integrity

• Sucrose density gradient fractionation can be performed before immunoprecipitation to separate different TBC1D7-containing complexes

• Control immunoprecipitations with non-specific IgG should be performed in parallel

• Validation of results with reciprocal immunoprecipitations using TSC1 or TSC2 antibodies is recommended

How can researchers effectively validate the specificity of TBC1D7 antibodies?

Thorough validation of TBC1D7 antibodies is essential for reliable research results. A comprehensive validation approach includes:

• siRNA/shRNA-mediated knockdown:

  • Transfect cells with TBC1D7-specific siRNA/shRNA and control sequences

  • Analyze protein levels by Western blot using the TBC1D7 antibody

  • The specific band should be significantly reduced in knockdown samples

• Genetic knockout models:

  • Use CRISPR/Cas9-generated TBC1D7 knockout cells or tissues

  • The specific TBC1D7 signal should be absent in knockout samples

• Overexpression systems:

  • Express tagged versions of TBC1D7 (e.g., FLAG-TBC1D7)

  • Confirm detection with both tag-specific and TBC1D7-specific antibodies

• Peptide competition assay:

  • Pre-incubate the antibody with excess immunizing peptide

  • The specific signal should be blocked in peptide-treated samples

• Cross-reactivity testing:

  • Test the antibody on samples from multiple species

  • Confirm species reactivity matches the manufacturer's claims

• Application-specific validation:

  • For immunofluorescence: Compare patterns with subcellular markers and verify signal loss in knockdown cells

  • For fractionation studies: Confirm TBC1D7 distribution patterns across fractions match expected profiles based on known interactions

• Reproducibility across lots:

  • Test multiple lots of the same antibody if possible

  • Maintain records of antibody performance across experiments

Researchers should document all validation steps and include appropriate controls in each experiment using TBC1D7 antibodies.

What are the best practices for detecting TBC1D7 in different cellular fractions and understanding its distinct pools?

TBC1D7 exists in multiple cellular pools, with approximately 40-50% associated with the TSC1-TSC2 complex and the remainder in free form . To effectively study these distinct populations:

Sucrose Density Gradient Fractionation Protocol:

• Prepare a 10-40% sucrose gradient in ultracentrifuge tubes.

• Load clarified cell lysates onto the gradient.

• Centrifuge at 100,000 × g for 16-18 hours at 4°C.

• Collect fractions from the top of the gradient (typically 15-20 fractions).

• Analyze fractions by Western blotting for TBC1D7, TSC1, and TSC2 .

Key Observations and Interpretations:

• TBC1D7 typically fractionates into two distinct pools:

  • Low-density fractions containing free TBC1D7

  • High-density fractions containing TSC1-TSC2-TBC1D7 complex

• In TSC1-knockdown cells, TBC1D7 shifts completely to low-density fractions

• In TSC2-knockdown cells, TBC1D7 shifts to low and intermediate-density fractions, consistent with its ability to bind TSC1 in the absence of TSC2

Stability Assessment of Different TBC1D7 Pools:

• Treat cells with cyclohexamide to block new protein synthesis.

• Collect samples at different time points (0, 1, 3, 6 hours).

• Perform fractionation and Western blotting.

• Compare degradation rates of TBC1D7 in different fractions.

Research has shown that free TBC1D7 (in low-density fractions) is more labile than complex-bound TBC1D7, with approximately 50% rapidly degraded even in the presence of TSC1 . This differential stability must be considered when interpreting TBC1D7 expression data.

Why might TBC1D7 antibodies show variable results in immunofluorescence studies, and how can these issues be resolved?

Inconsistent results in TBC1D7 immunofluorescence studies are common and stem from several factors:

Common Issues and Solutions:

Recommended Approach:

• Use genetic tools like mCherry knock-in at the endogenous TBC1D7 locus (as demonstrated in Drosophila models)

• Combine mCherry detection with antibody staining to validate antibody specificity

• Include co-staining with markers for TSC1, TSC2, and subcellular structures

• Document all experimental conditions in detail to enable reproducibility

Research has shown that finding antibodies that reveal specific localization patterns for endogenous TBC1D7 has been challenging, with many commercial antibodies failing validation tests for immunofluorescence applications .

How can researchers address challenges in detecting TBC1D7 in tissues where it is expressed at low levels?

Detecting low-abundance TBC1D7 in certain tissues presents significant challenges. Here are methodological approaches to overcome these limitations:

• Tissue-specific enrichment techniques:

  • Microdissection of relevant regions (e.g., insulin-producing cells)

  • Cell sorting to isolate specific cell populations

  • Subcellular fractionation to concentrate compartments where TBC1D7 is enriched

• Signal amplification methods:

  • Tyramide signal amplification (TSA) for immunohistochemistry

  • Proximity ligation assay (PLA) to detect TBC1D7 interactions with known partners (TSC1/TSC2)

  • Poly-HRP detection systems for Western blotting

• Concentration techniques for biochemical analysis:

  • Immunoprecipitation before Western blotting

  • Pooling of samples from similar tissues

  • Ultracentrifugation to collect specific cellular fractions

• Control experiments essential for validation:

  • Adjacent sections from TBC1D7 knockout models as negative controls

  • Positive control tissues known to express TBC1D7 (heart, insulin-producing cells)

  • Peptide competition assays to confirm signal specificity

• Alternative detection approaches:

  • RNA-based methods (in situ hybridization) to identify expression sites

  • CRISPR knock-in of epitope tags or fluorescent proteins at the endogenous locus

  • Mass spectrometry-based proteomics for unbiased detection

These approaches should be combined with rigorous validation to ensure the detected signals represent authentic TBC1D7 protein.

What experimental controls are critical when studying TBC1D7 stability and degradation with antibody-based approaches?

Studying TBC1D7 stability requires carefully designed controls to account for its unique degradation patterns and complex formation. Essential controls include:

• Genetic controls:

  • siRNA/shRNA knockdown of TBC1D7 to confirm antibody specificity

  • TSC1 and TSC2 knockdown/knockout models to understand complex-dependent stability effects

  • Rescue experiments with wild-type or mutant TBC1D7 to confirm specificity of observed effects

• Treatment controls:

  • Vehicle-only treatments matching the solvent used for inhibitors

  • Time-matched untreated samples for each timepoint in degradation studies

  • Positive control proteins with well-characterized degradation kinetics

• Protein stability assessment controls:

  • Proteasome inhibitors (MG132) to confirm proteasome-dependent degradation

  • Lysosome inhibitors (Bafilomycin A1) to assess lysosomal degradation contribution

  • Cyclohexamide treatment time courses with consistent dosing

• Fractionation controls:

  • Marker proteins for different fractions to confirm successful separation

  • Comparison of TBC1D7 stability in both low-density (free) and high-density (complex-bound) fractions

  • Controls for protein loading and transfer in each fraction

• Detection controls:

  • Multiple TBC1D7 antibodies targeting different epitopes

  • Detection of known stable proteins as loading controls

  • Quantification with appropriate normalization methods

Research has demonstrated that free TBC1D7 is significantly more labile than TSC-complex-bound TBC1D7, with approximately 50% rapidly degraded even in control cells . This differential stability must be accounted for when designing experiments and interpreting results.

How might new antibody technologies advance our understanding of TBC1D7's dual functions in TSC-dependent and independent pathways?

Emerging antibody technologies hold promise for unraveling TBC1D7's complex roles:

• Conformation-specific antibodies:

  • Development of antibodies that specifically recognize TBC1D7 in its TSC-bound versus free states

  • Antibodies that detect structural changes in TBC1D7 upon activation or inhibition

  • These could help distinguish between TBC1D7's roles in different cellular contexts

• Intrabodies and nanobodies:

  • Cell-permeable antibody fragments that can track TBC1D7 in live cells

  • May allow visualization of dynamic interactions with TSC1/TSC2 and other partners

  • Could be used to selectively inhibit specific TBC1D7 functions without affecting others

• Proximity-based labeling with antibody-enzyme fusions:

  • TBC1D7 antibodies conjugated to BioID or APEX2 for proximity labeling

  • Would allow identification of context-specific interaction partners

  • Could reveal distinct protein networks in TSC-dependent versus independent functions

• Antibody-based biosensors:

  • FRET-based sensors using TBC1D7 antibody fragments

  • Could detect conformational changes associated with different functional states

  • May provide real-time monitoring of TBC1D7 activity in different cellular compartments

• Single-domain antibodies for super-resolution microscopy:

  • Smaller antibody formats for improved spatial resolution

  • Could help resolve the precise subcellular localization of TBC1D7 in different contexts

  • May reveal previously undetected TBC1D7-containing structures

These technologies could help resolve the apparent contradiction between TBC1D7's established role as a third subunit of the TSC complex and its independent functions in insulin signaling and systemic growth regulation observed in Drosophila models .

What methodological approaches can help researchers integrate TBC1D7 antibody data with functional studies to understand disease mechanisms?

Integrating TBC1D7 antibody data with functional studies requires sophisticated methodological approaches:

• Spatiotemporal analysis in disease models:

  • Combine immunohistochemistry with tissue-specific genetic manipulations

  • Correlate TBC1D7 expression patterns with disease progression metrics

  • Use inducible systems to study acute versus chronic effects of TBC1D7 dysregulation

• Multi-omics integration:

  • Correlate antibody-based TBC1D7 protein levels with transcriptomics data

  • Integrate with phosphoproteomics to understand signaling pathway alterations

  • Combine with metabolomics to link TBC1D7 function to metabolic outcomes, particularly in insulin signaling contexts

• Patient-derived models:

  • Use antibodies to characterize TBC1D7 expression in patient samples with intellectual disability and megalencephaly

  • Develop patient-derived organoids to study tissue-specific effects of TBC1D7 mutations

  • Correlate TBC1D7 levels and localization with clinical phenotypes

• Quantitative microscopy approaches:

  • High-content screening with TBC1D7 antibodies to identify modulators of its expression or localization

  • Live-cell imaging with genetically encoded tags to track dynamics in real-time

  • Super-resolution microscopy to resolve TBC1D7-containing structures in health and disease states

• Functional rescue experiments:

  • Use antibodies to verify expression levels in rescue experiments

  • Test domain-specific mutants to map regions critical for different TBC1D7 functions

  • Employ tissue-specific expression systems to distinguish between local and systemic effects

These integrated approaches can help resolve the complex relationship between TBC1D7 dysfunction and disease manifestations, particularly the distinct phenotypes observed in TBC1D7 mutations (intellectual disability, megalencephaly) versus classic TSC presentations .